Navigation Links
Novel biomarkers in heart failure
Date:5/30/2009

Several new biomarkers have been recently described in Heart Failure (HF) syndrome either in stable chronic patients as in the settings of acute decompensation. Biomarkers are used to diagnose disease risk, to predict outcome and to tailor treatment to individuals.

Speaking at a press conference at Heart Failure 2009 in Nice, France, Prof Piotr Ponikowski, spokesperson for the European Society of Cardiology, presented these new findings, namely:

  • ST2 - a member of the interleukin (IL)-1 receptor family, markedly upregulated on the application of mechanical strain to cardiac myocytes; reported to be elevated in severe chronic HF, where independently predicts poor outcome; serial monitoring in acute decompensated HF may be useful for risk stratification
  • ultrasensitive troponins reflecting damage/loss of cardiomyocytes; elevation in chronic HF identifies poor outcome
  • advanced glycation end-products (AGEs) - molecules formed during a non-enzymatic reaction between proteins and sugar residues; there is an evidence that AGEs are related to the development and progression of HF in diabetic and non-diabetic patients;
  • adrenomedullin hormone which is a potent vasodilator, with inotropic and natriuretic properties; assessment of mid-regional part of the proadrenomedullin (MR-proADM test) has been proved to add additional information on standard of care in the diagnosis of acute HF and to be useful in prognostic evaluation of these patients
  • estrogens it has been recently shown that both low and high concentrations of circulating estradiol are powerful predictors of a poor prognosis in men with chronic HF; subjects with either reduced or increased concentrations of serum E2 have different clinical characteristics, suggesting that the underlying pathophysiological mechanisms are not the same

"Biomarker" is a very broad term that refers to parameter reflecting or characterizing a certain biological process. It may include variety of indices/parameters derived from clinical images, physiological tests, tissue biopsies, and even genetic variants, but most often, this term is reserved for blood or urine based assessments.

As examples of biomarkers assessed in the blood, which are already well established and widely used in clinical practice:

  • for lipid metabolism - blood cholesterol or LDL-cholesterol levels
  • for glucose metabolism glycated hemoglobin (HbA1c)
  • for kidney function creatinine, or recently cystatin C
  • for inflammation C-reactive protein (CRP)
  • for anemia hemoglobin
  • for cardiac function natriuretic peptides

Biomarker assessments are used in many clinical scenarios, in the emergency department, on the ward, in the outpatient clinic and in the near future at the patient's home (using telemedicine platform).

In heart failure, biomarkers aid in the diagnosis, help to assess co-morbidities in patients, may be useful in the risk stratification, monitoring of therapy and even serve as a therapeutic target. Importantly, many biomarkers may provide an insight into the pathophysiology of HF.

"The field of HF biomarkers continues to grow exponentially", explains Prof Ponikowski from Military Hospital in Wroclaw, Poland. "The following is a new classification, recently proposed by Prof Eugene Braunwald, according to which biomarkers can reflect/characterize different aspects of HF:

  • inflammation
  • oxidative stress
  • extracellular-matrix remodeling
  • neurohormones
  • myocyte injury
  • myocyte stress"

-
'/>"/>

Contact: ESC Press Office
press@escardio.org
33-062-241-8492
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Kyowa Hakko USA Announces GRAS Self-Affirmation for Novel Brain Health Ingredient Cognizin(R) Citicoline
2. Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research
3. A novel marker of colorectal carcinoma
4. Novel approach estimates nanoparticles in environment
5. The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market
6. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
7. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
8. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
9. Novel therapy may prove effective in treatment of 30 percent of cancers
10. Telesso Technologies wins Popular Science Invention Award for its novel peripheral IV catheter
11. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... ... 22, 2017 , ... Ecommerce sales have grown every year since the 1990’s, ... The consequences of rapid innovation and growth are often neglected in the name ... every business and individual’s job to give something back to the planet that provides ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... of ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and ... may have been used to remove decayed dental matter, and that teeth were then ...
(Date:4/21/2017)... LAKE CITY, Utah (PRWEB) , ... April 21, ... ... provider of wilderness therapy treatment for adolescents and young adults, has kicked off ... April 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy for ...
(Date:4/21/2017)... ... 2017 , ... The Patient Advocacy Community of The Beryl Institute presented Eve ... Ravich Patient Advocacy Award in recognition of her extraordinary contributions to the field ... at The Beryl Institute’s annual Patient Experience Conference on March 20 in ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness ... wish to overcome their mental health struggles. The Alive team uses advanced behavioral ... “Our approach in dealing with a mental health struggle is based on 10 ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research ... America Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, ... Segment Forecasts, 2014 - 2025" report to their offering. ... The Latin American ... 21.0 billion by 2025 Low drug registration cost ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
Breaking Medicine Technology: